新型双环胺类化合物作为治疗转移性乳腺癌或转移性肺癌的细胞周期蛋白依赖性激酶2（CDK2）抑制剂
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.
作者信息
Sabnis Ram W
机构信息
Smith Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
Abstract
Provided herein are novel bicyclic amines as CDK2 inhibitors, pharmaceutical compositions, use of such compounds in treating metastatic breast cancer or metastatic lung cancer and processes for preparing such compounds.
摘要
本文提供了作为细胞周期蛋白依赖性激酶2（CDK2）抑制剂的新型双环胺、药物组合物、此类化合物在治疗转移性乳腺癌或转移性肺癌中的用途以及制备此类化合物的方法。
相似文献
1
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
2
Novel Compounds as CDK2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
3
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
4
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
5
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
6
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.
ACS Med Chem Lett. 2024 Aug 22;15(9):1433-1434. doi: 10.1021/acsmedchemlett.4c00409. eCollection 2024 Sep 12.
7
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
ACS Med Chem Lett. 2025 Apr 2;16(5):732-733. doi: 10.1021/acsmedchemlett.5c00165. eCollection 2025 May 8.
8
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
9
Novel 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
ACS Med Chem Lett. 2025 Feb 14;16(3):371-372. doi: 10.1021/acsmedchemlett.5c00048. eCollection 2025 Mar 13.
10
1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
ACS Med Chem Lett. 2025 Mar 20;16(4):528-529. doi: 10.1021/acsmedchemlett.5c00128. eCollection 2025 Apr 10.
引用本文的文献
1
Identification and verification of immune and oxidative stress-related diagnostic indicators for malignant lung nodules through WGCNA and machine learning.
Sci Rep. 2025 Jul 1;15(1):22449. doi: 10.1038/s41598-025-04639-4.
本文引用的文献
1
Novel Compounds as CDK2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
2
Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma.
Cancer Cell Int. 2024 Nov 5;24(1):362. doi: 10.1186/s12935-024-03548-2.
3
Targeting CDK2 to combat drug resistance in cancer therapy.
Future Oncol. 2024 Dec;20(39):3325-3341. doi: 10.1080/14796694.2024.2416382. Epub 2024 Oct 29.
4
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8.
5
Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy.
Bioorg Chem. 2024 Feb;143:107045. doi: 10.1016/j.bioorg.2023.107045. Epub 2023 Dec 21.
6
The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
Nat Rev Clin Oncol. 2024 Feb;21(2):89-105. doi: 10.1038/s41571-023-00840-4. Epub 2023 Dec 11.
Zotero 插件